Cardiovascular risks post-COVID-19 vaccination: Key findings

FHS
October 3, 2024
10:29 am

Researchers explore the risks of cardiovascular and cerebrovascular events following vaccination against the COVID-19.

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference – Biotech Investments

Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference 01.02.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, February

February 2, 2024

HF-158K1 by HighField Biopharmaceuticals for Prostate Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Prostate Cancer.

July 6, 2024

No Improved Outcomes for HF Patients With Sleep Apnea Using ASV Breathing Devices

Breathing machines with adaptive servo-ventilation (ASV) did not improve survival or other clinical outcomes in patients with heart failure (HF) and reduced ejection fraction and

December 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.